Portfolio news 2010
Synairgen plc - Directorate appointment
28 Jun 2010
Synairgen plc (LSE: SNG), the respiratory drug discovery and
development company with a particular focus on viral defence in
asthma, COPD and flu, is pleased to announce the appointment of
Iain Peter Murray Buchanan to the Board.
Iain Buchanan, aged 57, has joined the Board as a non-executive
director with immediate effect. Iain is currently Chief Executive
Officer of Novexel SA ('Novexel'), a specialty pharmaceutical
company focused on novel anti-infectives. Iain joined Novexel at
its formation in 2004 and oversaw its recent sale to Astrazeneca in
March 2010. He has some 35 years' commercial experience in the
pharmaceutical and biotech industries. He joined Novexel from
Vertex Pharmaceuticals (Europe) Limited, where he was Managing
Director. Prior to Vertex, Iain was the Regional Licensing Director
of Cilag A.G. International, a division of Johnson & Johnson
based in Switzerland, where he managed Cilag's international
licensee business from 1987 to 1994. Prior to joining Cilag,
Iain was Marketing Director at Biogen in Switzerland, with
responsibility for business development activities in Europe.
He is also a non-executive director of NOXXON Pharma AG.
Simon Shaw, Chairman of Synairgen, commented, "I
am delighted to welcome Iain to the Board. Synairgen will benefit
significantly from his extensive business development and licensing
experience as we move towards realising the value of our interferon
beta programmes in the coming periods."
In accordance with the AIM Rules for Companies, the Company
confirms that there is no further disclosure obligation required,
pursuant to Schedule Two, Paragraph (g).
For further information, please contact:
+ 44 (0) 23 8051 2800
Simon Shaw, Chairman
Richard Marsden, Chief Executive Officer
+ 44 (0) 20 3206 7000
+ 44 (0) 20 7653 9850